JP2017537627A5 - - Google Patents

Download PDF

Info

Publication number
JP2017537627A5
JP2017537627A5 JP2017529682A JP2017529682A JP2017537627A5 JP 2017537627 A5 JP2017537627 A5 JP 2017537627A5 JP 2017529682 A JP2017529682 A JP 2017529682A JP 2017529682 A JP2017529682 A JP 2017529682A JP 2017537627 A5 JP2017537627 A5 JP 2017537627A5
Authority
JP
Japan
Prior art keywords
signaling domain
antigen receptor
chimeric antigen
domain
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017529682A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017537627A (ja
JP7098325B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/064303 external-priority patent/WO2016090369A1/en
Publication of JP2017537627A publication Critical patent/JP2017537627A/ja
Publication of JP2017537627A5 publication Critical patent/JP2017537627A5/ja
Priority to JP2022001433A priority Critical patent/JP7252379B2/ja
Application granted granted Critical
Publication of JP7098325B2 publication Critical patent/JP7098325B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017529682A 2014-12-05 2015-12-07 Cs1標的化キメラ抗原レセプター改変t細胞 Expired - Fee Related JP7098325B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022001433A JP7252379B2 (ja) 2014-12-05 2022-01-07 Cs1標的化キメラ抗原受容体修飾t細胞

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462088423P 2014-12-05 2014-12-05
US62/088,423 2014-12-05
PCT/US2015/064303 WO2016090369A1 (en) 2014-12-05 2015-12-07 Cs1 targeted chimeric antigen receptor-modified t cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022001433A Division JP7252379B2 (ja) 2014-12-05 2022-01-07 Cs1標的化キメラ抗原受容体修飾t細胞

Publications (3)

Publication Number Publication Date
JP2017537627A JP2017537627A (ja) 2017-12-21
JP2017537627A5 true JP2017537627A5 (https=) 2019-01-17
JP7098325B2 JP7098325B2 (ja) 2022-07-11

Family

ID=55069093

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017529682A Expired - Fee Related JP7098325B2 (ja) 2014-12-05 2015-12-07 Cs1標的化キメラ抗原レセプター改変t細胞
JP2022001433A Active JP7252379B2 (ja) 2014-12-05 2022-01-07 Cs1標的化キメラ抗原受容体修飾t細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022001433A Active JP7252379B2 (ja) 2014-12-05 2022-01-07 Cs1標的化キメラ抗原受容体修飾t細胞

Country Status (12)

Country Link
US (3) US10821161B2 (https=)
EP (2) EP4219530A1 (https=)
JP (2) JP7098325B2 (https=)
KR (1) KR102558502B1 (https=)
CN (2) CN114085856A (https=)
AU (2) AU2015357485B2 (https=)
BR (1) BR112017011893A2 (https=)
CA (1) CA2969704C (https=)
IL (3) IL290459B2 (https=)
MX (2) MX384964B (https=)
RU (1) RU2727451C2 (https=)
WO (1) WO2016090369A1 (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2934532B1 (en) 2012-12-20 2019-10-23 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
RU2763795C2 (ru) 2014-04-23 2022-01-11 Джуно Терапьютикс, Инк. Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии
BR112017011893A2 (pt) 2014-12-05 2018-07-24 City Of Hope células t modificadas no receptor de antígeno quimérico direcionado para cs1
ES2869972T3 (es) 2015-01-26 2021-10-26 Cellectis Sistemas de receptores de antígenos quiméricos dirigidos por mAb para clasificar/agotar células inmunitarias genomanipuladas
EP3347474B1 (en) 2015-09-11 2020-11-04 Biosceptre (UK) Limited Chimeric antigen receptors and uses thereof
EP3408297A2 (en) 2016-01-29 2018-12-05 Med Manor Organics, (P) Ltd A chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof
CN109414455B (zh) 2016-04-01 2023-01-20 凯德药业股份有限公司 Bcma结合分子及其使用方法
PT3436079T (pt) 2016-04-01 2021-10-06 Kite Pharma Inc Recetores de antigénios quiméricos e de células t e métodos de uso
KR20200068750A (ko) 2016-04-01 2020-06-15 카이트 파마 인코포레이티드 키메라 수용체 및 그의 사용 방법
JP7282521B2 (ja) 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Car t細胞療法のための方法および組成物
CN105949324B (zh) * 2016-06-30 2019-08-27 上海恒润达生生物科技有限公司 靶向gpc3的嵌合抗原受体及其用途
CN109476749A (zh) 2016-06-30 2019-03-15 豪夫迈·罗氏有限公司 改良的过继性t细胞疗法
WO2018064626A1 (en) * 2016-09-30 2018-04-05 Baylor College Of Medicine Adaptive chimeric antigen receptor t-cell design
WO2018156711A1 (en) * 2017-02-22 2018-08-30 H. Lee Moffitt Cancer Center And Research Institute, Inc. Il13ra2-binding chimeric antigen receptors
JP7178355B2 (ja) 2017-02-28 2022-11-25 エンドサイト・インコーポレイテッド Car t細胞療法のための組成物および方法
WO2018169922A2 (en) 2017-03-13 2018-09-20 Kite Pharma, Inc. Chimeric antigen receptors for melanoma and uses thereof
AU2018240111A1 (en) * 2017-03-20 2019-10-10 City Of Hope CS1 targeted chimeric antigen receptor-modified T cells for treatment of AL amyloidosis
ES3010117T3 (en) 2017-03-27 2025-04-01 Hoffmann La Roche Improved antigen binding receptors
SG10201912400VA (en) 2017-04-24 2020-02-27 Kite Pharma Inc Humanized antigen-binding domains against cd19 and methods of use
WO2018197675A1 (en) * 2017-04-28 2018-11-01 Julius-Maximilians-Universität Würzburg Ror1-specific chimeric antigen receptors (car) with humanized targeting domains
JP7560356B2 (ja) * 2017-08-01 2024-10-02 ユリウス-マクシミリアン-ウニヴェルシテート・ヴュルツブルク 急性骨髄性白血病を治療するためのflt3 car-t細胞及びflt3阻害剤の使用
IL272552B2 (en) 2017-08-11 2023-09-01 Idac Holdings Inc Traffic routing and switching between multiple access networks
EP3704230B1 (en) * 2017-11-01 2024-10-23 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
US11464803B2 (en) 2017-11-14 2022-10-11 Arcellx, Inc. D-domain containing polypeptides and uses thereof
AU2018369639C1 (en) * 2017-11-14 2025-04-03 Arcellx, Inc. D-domain containing polypeptides and uses thereof
WO2019099707A1 (en) 2017-11-16 2019-05-23 Kite Pharma, Inc Modified chimeric antigen receptors and methods of use
JP7433230B2 (ja) 2017-12-08 2024-02-19 ジュノー セラピューティクス インコーポレイテッド 細胞を培養するための無血清培地配合物およびその使用の方法
WO2019113557A1 (en) 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Process for producing a composition of engineered t cells
JP7549303B2 (ja) 2018-01-22 2024-09-11 エンドサイト・インコーポレイテッド Car t細胞の使用方法
CN112534044A (zh) 2018-02-16 2021-03-19 凯德药业股份有限公司 经修饰的多能干细胞及制备和使用方法
CN112105382A (zh) 2018-02-23 2020-12-18 恩多塞特公司 用于car t细胞疗法的顺序方法
EP3797164A4 (en) * 2018-05-21 2022-03-02 Biosceptre (Aust) Pty Ltd CHIMERIC ANTIGEN RECEPTORS WITH MODIFIED LINKER DOMAINS AND THEIR USES
US11951131B2 (en) 2018-07-03 2024-04-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-SLAMF7 chimeric antigen receptors
CA3108381A1 (en) * 2018-08-01 2020-02-06 City Of Hope Tag72 targeted chimeric antigen receptor modified t cells for treatment of tag72-positive tumors
WO2020025039A1 (zh) * 2018-08-03 2020-02-06 南京驯鹿医疗技术有限公司 表达嵌合抗原受体的t细胞、该嵌合抗原相关表达载体以及它们的应用
CN113474450A (zh) 2018-08-09 2021-10-01 朱诺治疗学股份有限公司 产生工程化细胞的方法以及所述工程化细胞的组合物
KR102840400B1 (ko) 2018-12-12 2025-08-04 카이트 파마 인코포레이티드 키메라 항원 수용체 및 car-t 세포 및 사용 방법
JP7286796B2 (ja) 2019-04-03 2023-06-05 プレシジョン バイオサイエンシズ,インク. マイクロrna適合shrna(shrnamir)を含む遺伝子改変免疫細胞
CN114051532A (zh) * 2019-05-24 2022-02-15 希望之城公司 用于治疗ccr4阳性恶性肿瘤的经ccr4靶向性嵌合抗原受体修饰的t细胞
CN114222763A (zh) * 2019-06-19 2022-03-22 尤利乌斯·马克西米利安维尔茨堡大学 在嵌合抗原受体设计中实现的超模块化IgG3间隔区结构域和多功能位点
CN112442126B (zh) * 2019-09-04 2022-07-29 杭州济元基因科技有限公司 一种抗人cs1抗原的单克隆抗体及其car-t细胞
US20230348854A1 (en) * 2020-05-08 2023-11-02 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Chimeric antigen receptors (cars) targeting natural killer cells
WO2021242719A1 (en) * 2020-05-27 2021-12-02 The Medical College Of Wisconsin, Inc. Improved lentiviral vector transfer plasmid and methods of use
CN114286691B (zh) * 2020-08-06 2024-08-06 武汉思安医疗技术有限公司 Cs1-抗体和抗cs1-car-t细胞
WO2022034022A1 (en) * 2020-08-10 2022-02-17 Julius-Maximilians-Universität Würzburg Siglec-6-binding polypeptides
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
WO2022212525A2 (en) * 2021-03-30 2022-10-06 City Of Hope Car t cell therapy and ifn gamma
CN117083292A (zh) * 2021-04-02 2023-11-17 科济生物医药(上海)有限公司 Cs1工程化细胞及其组合物
WO2023107898A1 (en) * 2021-12-06 2023-06-15 The Children's Hospital Of Philadelphia Dual targeting of pediatric malignancies through car t-cells secreting bispecific innate immune cell engagers (bices)
CN116410331B (zh) * 2021-12-31 2024-01-30 合源生物科技(天津)有限公司 靶向cs1的嵌合抗原受体、靶向bcma/cs1的双特异性嵌合抗原受体及其应用
JP2025512797A (ja) * 2022-03-25 2025-04-22 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 改善されたキメラ受容体
WO2024114691A1 (en) * 2022-12-02 2024-06-06 Guangzhou Litai Biotechnology Co., Ltd. Human cs1 car-t cells
CN119019554B (zh) * 2023-05-25 2025-08-12 东莞市朋志生物科技有限公司 抗白介素6抗体、检测白介素6的试剂和试剂盒

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002063A1 (en) 1989-08-11 1991-02-21 Amrad Corporation Limited Improvements in granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
KR20130108481A (ko) 2005-08-19 2013-10-02 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
WO2007047829A2 (en) 2005-10-19 2007-04-26 Laboratoires Serono S.A. Novel heterodimeric proteins and uses thereof
GB0523954D0 (en) * 2005-11-24 2006-01-04 Ucb Celltech Bioassays
WO2007146968A2 (en) * 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
US8551715B2 (en) 2010-02-12 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for identifying and isolating cells expressing a polypeptide
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
JP6850528B2 (ja) * 2012-02-13 2021-03-31 シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート 二重特異性キメラ抗原受容体およびその治療的使用
US9359447B2 (en) 2012-03-23 2016-06-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin chimeric antigen receptors
JP6293731B2 (ja) * 2012-04-05 2018-03-14 エーシー イミューン エス.エー. ヒト化タウ抗体
CN115028735A (zh) * 2013-05-03 2022-09-09 俄亥俄州创新基金会 Cs1-特异性嵌合抗原受体工程化的免疫效应细胞
US20160333108A1 (en) * 2014-01-13 2016-11-17 Stephen J. Forman CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE
ES3063961T3 (en) 2014-02-14 2026-04-21 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
WO2015166056A1 (en) * 2014-05-02 2015-11-05 Cellectis Cs1 specific multi-chain chimeric antigen receptor
BR112017011893A2 (pt) * 2014-12-05 2018-07-24 City Of Hope células t modificadas no receptor de antígeno quimérico direcionado para cs1
AU2018240111A1 (en) * 2017-03-20 2019-10-10 City Of Hope CS1 targeted chimeric antigen receptor-modified T cells for treatment of AL amyloidosis

Similar Documents

Publication Publication Date Title
JP2017537627A5 (https=)
JP2019500894A5 (https=)
RU2017121826A (ru) Т-клетки, модифицированные химерным рецептором антигена, нацеленным на cs1
JP6968389B2 (ja) Bcmaに結合するキメラ抗原受容体(car)及びその応用
JP2023139070A5 (https=)
IL292650B1 (en) COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Ra2
JP2016538855A5 (https=)
ES2800906T3 (es) Métodos mejorados para producir terapias celulares adoptivas
IL259120A (en) Her2-targeted antigen chimeric receptors2
JP2017500869A5 (https=)
JP2018029594A5 (https=)
RU2018113510A (ru) Химерные рецепторы антигена, нацеленные на psca
JP2018532407A5 (https=)
JP2017537622A5 (https=)
JP2019528769A5 (https=)
BR112020007576A2 (pt) composições e métodos para degradação de proteína seletiva
JP2018518990A5 (https=)
JP2020512019A5 (https=)
JP2018531014A5 (https=)
JP2017538401A5 (https=)
JP2017513478A5 (https=)
JP2020513754A5 (https=)
JP2016520074A5 (https=)
JP2017535292A5 (https=)
FI3824905T3 (fi) Menetelmä ja koostumuksia soluimmunoterapiaa varten